Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract

AIDS

Volumn 22, Issue 14, 2008, Pages 1894-1896

  Pasquier, Christophe J M ^a,b,c   Moinard, Nathalie ^c   Sauné, Karine ^a,b,c   Souyris, Corinne ^a,b   Lavit, Michel ^a   Daudin, Myriam ^c   Izopet, Jacques ^a,b,c   Bujan, Louis ^c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIVIRUS AGENT; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; RITONAVIR; RNA; TENOFOVIR; ZIDOVUDINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; MALE; MALE GENITAL SYSTEM; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; MALE; SEMEN; VIRAL LOAD; VIREMIA; VIRUS SHEDDING;

EID: 66349118092     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283101281     Document Type: Letter

References (20)

1. Kalichman SC, Di Berto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2008; 35:55-60.
2. Lowe SH, Wensing AM, Droste JA, ten Kate RW, Jurriaans S, Burger DM, et al. No virological failure in semen during properly suppressive antiretroviral therapy despite subthera-peutic local drug concentrations. HIV Clin Trials 2006; 7:285-290.
3. Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, Pomerantz RJ. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339:1803-1809.
4. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in nonblood compartments: clinical correlations. HIV Clin Trials 2002; 3:27-35.
5. CraigoJK, Patterson BK, ParanjpeS, Kulka K, DingM, MellorsJ, et al. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:1196-1209.
6. Leruez-VilleM, Dulioust E, Costabliola D, Salmon D, Tachet A, Finkielsztejn L, et al. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). AIDS 2002; 16: 486-488.
7. Delobel P, Nugeyre MT, Cazabat M, Pasquier C, Marchou B, Massip P, et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007; 45: 1572-1580.
8. Ghosn J, Chaix ML, Peytavin G, Bresson JL, GalimandJ, Girard PM, et al. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/ lamivudine. J Antimicrob Chemother 2008; 61:1344-1347.
9. Coombs RW, Lockhart D, Ross SO, Deutsch L, Dragavon J, Diem K, et al. Lower genitourinary tract sources of seminal HIV. J Acquir Immune Defic Syndr 2006; 41:430-438.
10. Le Tortorec A, Le Grand R, Denis H, Satie AP, Mannioui K, Roques P, et al. Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS ONE 2008; 3:e1792.
11. SadiqST, TaylorS, KayeS, BennettJ,JohnstoneR, Byrne P, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16:219-225.
12. Bujan L, Daudin M, Matsuda T, Righi L, Thauvin L, Berges L, et al. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS 2004; 18:757-766.
13. Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18:1958-1961.
14. Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, et al. Lopinavir/ritonavir combined with twice-daily 400 mg indina-vir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother 2004; 54:498-502.
15. Chan DJ, RayJE. Quantification of antiretroviral drugsfor HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis. J Pharm Pharmacol 2007; 59:1451 -1462.
16. Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, Cohen MS. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-F189.
17. Eyre RC, Zheng G, Kiessling AA. Multiple drug resistance mutations in human immunodeficiency virus in semen but not blood of a man on antiretroviral therapy. Urology 2000; 55:591.
18. Liuzzi G, Chirianni A, Zaccarelli M, Zinzi D, Esposito V, Guadagnino V, et al. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo 2004; 18:509-512.
19. Ghosn J, Viard JP, Katlama C, de Almeida M, Tubiana R, Letourneur F, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pretreated HIV-infected men. AIDS 2004; 18:447-457.
20. Barreiro P, Castilla JA, Labarga P, Soriano V. Is natural conception a valid option for HIV-serodiscordant couples? Hum Reprod 2007; 22:2353-2358.